TYRP1 and melanoma: To confirm the antigen specificity of the 20D7SL-derived TYRP1 CAR-T cell therapy, we next knocked out the TYRP1 protein in three patient-derived TYRP1high melanoma cell lines (M207, M249, and M285, Supplementary Fig. 4a–e) and measured cytotoxicity and cytokine release upon co-culture of 20D7SL-28ζ and 20D7SL-BBζ CAR-T cell with the parental TYRP1high cell lines or their TYRP1-knock out counterparts.